Proactive - Interviews for investors
Nyrada Phase 2 trial targets heart attack damage
Nyrada Inc CEO James Bonnar spoke about the company's upcoming Phase 2 clinical trial for its drug candidate, Zoltrip. The trial will target STEMI patients to assess safety and efficacy, addressing reperfusion injury, a condition that can worsen heart damage after blood flow is…